Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Otitis-prone children produce functional antibodies to pneumolysin and pneumococcal polysaccharides

The production of functional antipneumococcal antibodies in otitisprone children demonstrates that they respond to the current pneumococcal conjugate vaccine (PCV)and are likely to respond to pneumolysin-based vaccines as effectively as healthy children.

Research

Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study

Immune responses after the initial vaccination persisted for the 12 months studied, with little additional response after the booster dose at 6 months

Research

HPV.edu study protocol: A cluster randomised controlled evaluation of education, decisional support and logistical strategies...

The National Human Papillomavirus (HPV) Vaccination Program in Australia commenced in 2007 for females and in 2013 for males, using the quadrivalent HPV...

Research

Advancing the management and control of typhoid fever: a review of the historical role of human challenge studies

Improved understanding of Salmonella Typhi infection can help accelerate the development of improved vaccines and diagnostic tests necessary for disease control

Research

A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults

No currently licensed and available vaccine has been shown to provide broad protection against endemic MnB disease.

News & Events

Video: Flu vaccine Q&A

It's that time of year again... Flu vaccine time! Watch Dr Chris Blyth answer commonly asked questions in the video below.

News & Events

The Kids Research Institute Australia research ensures kids are protected against whooping cough

Research by The Kids Research Institute Australia will soon ensure young children are better protected against whooping cough.

Research

The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February – August 2021

To assess the short term safety of the COVID-19 vaccines Comirnaty (Pfizer–BioNTech BNT162b2) and Vaxzevria (AstraZeneca ChAdOx1) in Australia.

Research

Influenza hospitalizations in Australian children 2010–2019: The impact of medical comorbidities on outcomes, vaccine coverage, and effectiveness

Children with comorbidities are at greater risk of severe influenza outcomes compared with healthy children. In Australia, influenza vaccination was funded for those with comorbidities from 2010 and all children aged <5 years from 2018. Influenza vaccine coverage remains inadequate in children with and without comorbidities.